Latest neck cancers Stories
CALGARY, Nov. 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
--Company to Host Conference Call-- CALGARY, Oct. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has reached an agreement with the U.S.
According to a recent study, long-term pot smokers are 62 percent less likely to develop head and neck cancers than people who do not smoke marijuana.
Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy.
BUFFALO, N.Y., May 22 /PRNewswire-USNewswire/ -- Researchers at Roswell Park Cancer Institute (RPCI) in Buffalo, New York, are strongly advocating a national discussion about the need to vaccinate both young men and women against HPV 16 to prevent head & neck cancers.
CALGARY, Nov. 4 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results for the three and nine-month periods ended September 30, 2008.
Oncolytics Biotech has initiated patient enrollment in a Phase II clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.
CALGARY, Sept. 8 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc.
Azaya Therapeutics, Inc., announced today that it has signed a licensing agreement to further develop a breakthrough technology that uses liposomes to deliver radiation through direct injection into head and neck tumors, shrinking the tumor, delaying recurrence and avoiding the collateral tissue damage that often accompanies all other forms of radiation therapy.
Oncolytics Biotech has announced that following FDA review, the company is initiating a US Phase II clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.
- Growing in low tufty patches.